Efficacy of Kangfuxin Liquid combined with mesalazine in treating elderly patients with ulcerative colitis
-
摘要: 目的 探讨康复新液联合美沙拉嗪对老年溃疡性结肠炎患者治疗效果、不良反应及炎症反应的影响。 方法 选择106例老年溃疡性结肠炎患者为研究对象,采用随机数字表法分为对照组与研究组,每组53例。对照组采用常规对症治疗与美沙拉嗪治疗,研究组在此基础上应用康复新液治疗。比较2组临床疗效、不良反应、治疗前后炎症因子［超敏C反应蛋白(hs-CRP)、肿瘤坏死因子-α(TNF-α)、白细胞介素-23(IL-23)与白细胞介素-17(IL-17)］水平以及6个月内疾病复发情况。 结果 研究组治疗总有效率为96.23%, 高于对照组的83.02%, 差异有统计学意义(P<0.05); 2组治疗期间不良反应发生率比较,差异无统计学意义(P>0.05); 治疗后,研究组hs-CRP、TNF-α、IL-23和IL-17水平均低于对照组,差异有统计学意义(P<0.01); 研究组6个月内复发率为7.55%, 低于对照组的22.64%, 差异有统计学意义(P<0.05)。 结论 康新复液联合美沙拉嗪治疗老年溃疡性结肠炎患者疗效确切,可有效缓解炎症反应,降低复发率,安全可靠。Abstract: Objective To explore the effects of Kangfuxin Liquid combined with mesalazine on therapeutic effect, adverse reactions and inflammatory reactions in elderly patients with ulcerative colitis. Methods A total of 106 elderly patients with ulcerative colitis were selected as study objects, and were divided into two groups by random number table method. The control group(n=53)was treated with conventional symptomatic treatment and mesalazine, and the study group(n=53)was treated with Kangfuxin Liquid on basis of the control group. The clinical efficacy, adverse reactions, levels of inflammatory factors ［hypersensitive C-reactive protein(hs-CRP), tumor necrosis factor-α(TNF-α), interleukin-23(IL-23)and interleukin-17(IL-17)］ before and after treatment, and the recurrence of the disease within 6 months were compared between the two groups. Results The total effective rate of the study group was 96.23%, which was significantly higher than 83.02%of the control group(P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05). After treatment, the levels of hs-CRP, TNF-α, IL-23 and IL-17 in the study group were significantly lower than those in the control group(P<0.01). The recurrence rate of the study group within 6 months was 7.55%, which was significantly lower than 22.64% of the control group(P<0.05). Conclusion Kangfuxin Liquid combined with mesalazine is effective, safe and reliable in the treatment of elderly patients with ulcerative colitis, and can effectively relieve the inflammatory response, and reduce the re-occurrence rate.
-
-
吴美玉, 黄永德, 陈建兴, 等. 康复新液、地衣芽孢杆菌及美沙拉嗪联合对活动期溃疡性结肠炎疗效及对IL-23、IL-17、氧自由基、肠道菌群的改善作用[J]. 解放军医药杂志, 2020, 32(2): 79-83. 秦晓纲. 清肠化湿灌肠方直肠滴入治疗激素抵抗型重症溃疡性结肠炎的疗效观察[J]. 实用临床医药杂志, 2018, 22(11): 62-65. 刘超, 杨静, 朱凤池, 等. 甲硝唑联合康复新液保留灌肠治疗溃疡性结肠炎的临床研究[J]. 河北医药, 2019, 41(15): 2325-2327 , 2331.
MORILLA I, UZZAN M, LAHARIE D, et al. Colonic MicroRNA profiles, identified by a deep learning algorithm, that predict responses to therapy of patients with acute severe ulcerative colitis[J]. Clin Gastroenterol Hepatol, 2019, 17(5): 905-913.
SEHGAL P, COLOMBEL J F, ABOUBAKR A, et al. Systematic review: safety of mesalazine in ulcerative colitis[J]. Aliment Pharmacol Ther, 2018, 47(12): 1597-1609.
王震. 康复新液治疗对溃疡性结肠炎患者炎性、免疫、氧化指标及血管因子的影响[J]. 海南医学院学报, 2018, 24(23): 2041-2044 , 2049.
薛雾松, 刘仍海. 康复新液对老年UC患者的治疗效果及对血清MDA、SOD、hs-CRP水平的影响[J]. 解放军预防医学杂志, 2018, 36(10): 1248-1250 , 1254.
高显奎, 赵太云, 陆兴俊, 等. 美沙拉秦缓释颗粒联合康复新液保留灌肠治疗溃疡性结肠炎患者的疗效及安全性分析[J]. 解放军预防医学杂志, 2019, 37(8): 45-46. 王佳, 陈爱霞, 李洪超. 康复新液联合双歧杆菌三联活菌胶囊对溃疡性结肠炎患者血清LPO、SOD水平及生活质量的影响[J]. 中国现代医学杂志, 2019, 29(15): 82-86. 李辉标, 陈新林, 陈慕媛, 等. 康复新液联用益生菌治疗溃疡性结肠炎Meta分析[J]. 辽宁中医杂志, 2018, 45(10): 2037-2041. 张晓慧. 单用美沙拉嗪及联用双歧三联活菌治疗溃疡性结肠炎的疗效及对肿瘤坏死因子-α、白细胞介素-6及白细胞介素-8的影响分析[J]. 实用临床医药杂志, 2018, 22(3): 112-114. DULAI P S. Methotrexate monotherapy for induction and maintenance of clinical remission in ulcerative colitis: dead on arrival[J]. Gastroenterology, 2018, 155(4): 967-969.
刘亮, 李春涛, 牛应林, 等. 益生菌联合康复新液在活动期轻中度溃疡性结肠炎患者中的临床效果分析[J]. 中国医刊, 2017, 52(5): 24-26. 陈立冬, 刘智慧, 于蕊. 康复新液灌肠联合美沙拉嗪治疗溃疡性结肠炎疗效研究[J]. 陕西中医, 2019, 40(9): 1187-1189. -
期刊类型引用(13)
1. 李洪霞. 康复新液灌肠联合美沙拉嗪对溃疡性结肠炎患者炎症反应及疾病复发情况的影响. 反射疗法与康复医学. 2024(15): 135-137+145 . 
百度学术
2. 焦一鹏. 培菲康联合美沙拉嗪与康复新液对溃疡性结肠炎患者炎症因子及不良反应的影响. 中国现代药物应用. 2024(20): 87-90 . 百度学术
3. 王少华，王崇文. 康复新液灌肠联合美沙拉嗪治疗溃疡性结肠炎的疗效研究. 天津药学. 2024(06): 158-162 . 百度学术
4. 贾慧宇，张霞，张斌，宋维轩，康金旺，陈云飞. 美沙拉嗪联合康复新液治疗老年溃疡性结肠炎临床观察. 河北北方学院学报(自然科学版). 2023(02): 25-28 . 百度学术
5. 苗强，杨子龙，闫富俊. 柳氮磺吡啶与美沙拉嗪治疗溃疡性结肠炎的疗效比较. 中国肛肠病杂志. 2023(04): 50-51 . 百度学术
6. 陈莉，李小刚，王建丰，郝仁山，项伟艳，谭普芳，朱琦. 老年溃疡性结肠炎患者血清IL-33及粪钙卫蛋白水平表达的临床意义及对预后的影响. 中国老年学杂志. 2023(09): 2094-2097 . 百度学术
7. 李萍. 康复新液联合美沙拉嗪治疗溃疡性结肠炎的临床效果及对血清炎性因子的影响. 临床合理用药. 2023(14): 83-86 . 百度学术
8. 张秋芹. 康复新液联合美沙拉秦对溃疡性结肠炎的IL-1、IL-8、TNF-α、T细胞亚群水平的影响. 中华养生保健. 2023(22): 12-15 . 百度学术
9. 张敏，陈庆，魏书青，马静，高金昙. 康复新液辅助抗结核化疗方案治疗肠结核的临床研究. 中国医院用药评价与分析. 2022(01): 29-31+37 . 百度学术
10. 陈晖，单君康. 康复新液与美沙拉嗪联合治疗对溃疡性结肠炎患者的临床疗效观察. 现代医学与健康研究电子杂志. 2022(02): 22-25 . 百度学术
11. 谭德胜，梁心慧，刘杨基，陈斌，丁富莲，林凯生. 康复新液联合四联疗法治疗HP阳性胃溃疡的效果. 中国医药科学. 2022(11): 106-109 . 百度学术
12. 王淑敏，崔龙灿. 柳氮磺吡啶与美沙拉嗪治疗溃疡性结肠炎的临床效果比较. 临床医学研究与实践. 2022(25): 63-65 . 百度学术
13. 孟海琴. 观察黛力新结合美沙拉嗪治疗结肠炎的临床效果. 智慧健康. 2022(28): 74-76+81 . 百度学术
其他类型引用(1)
计量
- 文章访问数: 634
- HTML全文浏览量: 162
- PDF下载量: 22
- 被引次数: 14
下载:
苏公网安备 32100302010246号
